HA35
PreclinicalSmall molecule
HA35 is one of 35 small molecule programs targeting Myofascial Pain Syndrome. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Rectal Cancer
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Capeox
GSKPhase 3
Stivarga
BayerPhase 2
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Tukysa
PfizerPhase 2
PD-1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HA35. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNakhia Impex LLC